Active projects in GHU Countries
46
The partner is executing the program in the relevant country *
Treatments & value chain
506, 130
Total # of Patients treated for NCDS *
Patient care
369, 133
Total # of beneficiaries reached through programs **
HCP empowerment
6,774
Total # HCWs and HCPs trained **
* Sanofi internal data at end Q1 2024
** Sanofi internal data at end Q4 2023
Delivering sustainable impact 
We believe that the only way to improve the health of more people in low and middle income countries is through a sustainable, long-term commitment and approach, rooted in the principles of a primary health organization.
That is why we have developed an accessible solution called Impact that allows us to bring to market a range of standard-of-care treatments in your country, equivalent to brands marketed in other countries.
Our purpose
Availability of treatments
Improving access to Sanofi quality treatments through innovative and inclusive healthcare.
Affordable
treatments
Providing quality treatments at affordable prices to widen access to standard-of-care medicines.
Strengthening
health systems
Supporting local health systems through impactful partnerships that drive sustainable change.
Impact Products
Discover our portfolio of Impact products with standard-of-care medicines for non-communicable diseases such as cardiovascular diseases and diabetes.
Therapeutic areas
Diabetes
Explore our resources to support effective care for people living with diabetes in the most vulnerable communities.
Cardiovascular diseases
Get an overview of our work with cardiovascular diseases and how we can help support you and your patients.
Oncology
Discover our resources aimed at delivering effective care for oncology patients.
Stay up to date with the latest news
Take a moment to explore news and highlights about our ongoing initiatives.
Have a question
or need support?
Find answers to the most common questions in our FAQ. Maybe your question has already been asked. If you don't find your answer, you're always welcome to contact us.
MAT-GLB-2304595 (v3.0)
DOP: April 2024